RBC Capital Keeps Their Buy Rating on PTC Therapeutics (PTCT)


RBC Capital analyst Brian Abrahams reiterated a Buy rating on PTC Therapeutics (NASDAQ: PTCT) today and set a price target of $51. The company’s shares opened today at $40.81.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.5% and a 55.9% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Intra-Cellular Therapies, and Alder Biopharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PTC Therapeutics with a $48 average price target, implying a 17.6% upside from current levels. In a report released yesterday, William Blair also upgraded the stock to Buy.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $52.95 and a one-year low of $14.56. Currently, PTC Therapeutics has an average volume of 1.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts